

MODIFICATIONS IN VALUES OF GASTRIN SERUM AND CARBONIC ANHYDRASE AFTER THERAPY TO ERADICATE THE HELICOBACTER PYLORI IN DUODENAL ULCER PATIENTS

CLAUDIA ANCA DUME^{1*}, IOAN PUSCAS², MARCELA COLTAU²

1 Regional Gastroenterology and Hepatology Institute "Prof. O. Fodor" Cluj Napoca; 2 Municipal Hospital "Prof. Dr. Ioan Puscas" Simleu Silvaniei

ABSTRACT. Many researchers have suggested that measuring the levels of gastrin and pepsinogen during the treatment to eradicate *H. pylori* infection may be useful to assess whether the treatment is effective or not. The gastrin which is a key- enzyme in modulating gastric acid secretion is also a direct activator of carbonic anhydrase (CA). In our work we have studied the effect of treatment to eradicate *H. pylori* infection on the levels of serum gastrin and carbonic anhydrase IV in the gastric mucosa, in the case of two groups of patients with UD and positive *H. pylori* diagnostics who were treated by means of triple therapy, and respectively quadruple therapy for 10 days. Endoscopy with biopsy sampling was performed in the case of all patients. The study results prove the implication of isoenzyme CA IV of the gastric mucosa and the gastrin in the action of therapy mechanisms to eradicate *H. pylori* infection. Following the treatment to eradicate the *H. pylori* infection one reveals a decrease of CA IV gastric activity by 64% in the Group no. 1 patients, and 78% in the Group no. 2 patients, while the levels of serum in gastrin decrease by 58% in Group no. 1 and by 69% in group no.2, respectively.

KEYWORDS: Helicobacter pylori, Carbonic anhydrase, Duodenal ulcer, Gastrin

INTRODUCTION

The *Helicobacter pylori* infection is one of the most common infections of the human species and is common all over the world and virtually all people are susceptible. It is believed that over half of the world population is infected with *H. pylori*, as there are areas where virtually the entire population is infected since childhood. This infection is more common in developing countries, where prevalence in adults reaches 80-90%, as compared to the developed countries where this infection does not exceed 60%. Untreated, and once appeared the infection persists for a lifetime. Therefore the prevalence of infection with *H. pylori* is the most useful parameter

for studying the epidemiology of this bacterium. (konturek, 2003)

The research methods the epidemiologists have at their disposal to determine the presence of *H. pylori* infection vary, each technique showing its string and weak points at the same time. The standard method of determining the situation of a person regarding his/her infection with *H. pylori* and that would enable correlations with possible injuries, is the endoscopic method accompanied by biopsy sampling from different parts of the stomach, particularly in the gastric (pyloric) antrum. Practical and ethical drawbacks make this method unacceptable to be applied for large population studies. However, studies on volunteers were performed

using endoscopy as the reference technique, the aim of these studies being to assess other methods of establishing *H. pylori* infection (serology, breath tests). (Kusters et al., 2006; Stenström et al., 2008; Logan et al., 2001)

Initially, the first marker that suggests the presence of *H. pylori* infection was the presence of associated diseases such as gastritis, peptic ulcer or gastric adenocarcinoma. (Harry et al., 2001)

It was found later that there are significant changes in some laboratory parameters, modifications that may be associated with *H. pylori* infection. There is a large share of suggestive biochemical markers to highlight the active or passive presence of *H. pylori* infection. For example, one of these biochemical markers proving an active infection with *H. pylori* is the increased serum gastrin stimulated by food (Graham et al., 1990; Levi et al., 1989; Prewett et al., 1991) or high levels of pepsinogen which is known as a risk factor in the development of duodenal ulcer. (Rotter et al., 1979)

Many researchers have suggested that measuring levels of gastrin and pepsinogen during the treatment to eradicate *H. pylori* infection may be useful to assess whether the treatment is effective or not. (Calam, 1997; Chen et al., 1994; Maconi et al., 1997)

Regarding the gastrin, it is well known its role in the mechanism of gastric acid secretion, as the gastrin is one of the endogenous activators of acid secretion. (Grossman, 1978) The studies conducted by Prof. Puscas and his team proved once again that this hormone is also a direct activator of carbonic anhydrase (CA), (Pușcaș et al., 1994) and the enzyme with a key role in modulating gastric acid secretion. (Pușcaș, 1998)

THE AIM OF THE STUDY

Based on the data here above, this paper presents the results of the study we conducted on the effect of treatment to eradicate *H. pylori* infection on the levels of serum gastrin values and carbonic anhydrase IV in the gastric mucosa in patients with duodenal ulcer.

MATERIAL AND METHOD

We selected a total number of 40 patients, volunteers, male, aged 28-65 years with duodenal ulcer

and *H. pylori* positive. They were divided into 2 groups depending on the treatment they were applied for 10 days, respectively:

Patients Group no. 1 - Triple therapy, the following pairing respectively:

- Omeprazole 40 mg / day
- Amoxicillin 2 g / day
- Clarithromycin 1 g / day

Group no. 2 - Quadruple therapy, the following pairing respectively:

- Omeprazole 40mg / day
- *Bismuth. subnitric.* (De-Nol) 4x120 mg / day
- Tetracycline 2 g / day
- Metronidazole 1.5 g / day

Both before and after treatment, all patients were performed endoscopic examination with biopsy sampling.

Biopsies were used to determine *H. pylori* infection by means of Urease method. (Westblom et al., 1999; Wilcox et al., 1996) The test is read at 30, the positiveness speed being correlated with the number of bacteria present in the biopsy. (Woo et al., 1996)

Moreover one separated the carbonic anhydrase IV from biopsy samples (Maren et al., 1993) and then, by means of stopped-flow method (Khalifah, 1971), one determined the activity of this isoenzyme isolated from the parietal cells of gastric mucosa. Measuring the CA IV activity was performed by means of a rapid kinetic spectrophotometer HI-TECH SF-51MX manufactured in England.

The CA activity was calculated using the following formula:

$$A = \frac{T_0 - T}{T} \quad [\text{UE/ml}]$$

where T_0 is the uncatalyzed reaction time and T is the time of the catalyzed reaction by CA IV.

All patients were collected venous blood to dosing the serum gastrin by immunoenzymatic method with detection by chemiluminescence. (Fischbach, 2009)

The study was conducted in accordance with the Declaration of Helsinki.

Statistical analysis of data was performed by computing using the software packages Microsoft Excel and EpiInfo 6.0.

The study results were expressed as mean \pm standard deviation, calculated in the framework of Microsoft Excel software according to the following formulas:

$$m = \sum xi / n$$

Where:

m = arithmetic mean;

xi = the result of individual determinations;

n = number of individual determinations.

$$SD = \sqrt{[\sum xi^2 - (\sum xi)^2/n] / (n-1)}$$

Where:

SD = standard deviation, indicating scattering limits of n parameters (xi) individually determined as against the average;

xi = the result of individual determinations;

n = number of individual determinations.

For each parameter analyzed, only the values falling within the reference parameters range, defined as mean \pm 2 \times SD, were included in the final statistical calculation.

Comparison of the results was performed by using the t Student test or the variance analysis (ANOVA) test. The values p < 0.05 were considered statistically significant.

RESULTS

The results of the study are presented in Tables 1 and 2 and in the Graphs 1 and 2 hereunder.

Table no. 1: Changes in CA IV gastric activity at patients with duodenal ulcer after anti H. pylori therapy


Group of patients	CA IV (UE/ml) Before treatment	CA IV (UE/ml) After treatment	Statistical value
1	1.746 \pm 0.149 UE/mg	0.628 \pm 0.086	p<0.05
2	1.837 \pm 0.152	0.404 \pm 0.055	p<0.05

Normal values of gastric CA IV: 1.00 to 1.30 EU / ml


Table no. 2: Changes in serum gastrin values in patients with duodenal ulcer after anti H. pylori therapy

Group of patients	Gastrin (pg/ml) Before treatment	Gastrin (pg/ml) After treatment	Statistical value
1	273 \pm 19	110 \pm 14	p<0.05
2	348 \pm 27	106 \pm 11	p<0.05

Normal values of serum gastrin: 13 to 115 pg / ml



Graph no. 1 - Bacterial load, and the percentage of *H. pylori* infection in the 2 groups of patients studied



Graph no. 2 Parallel decrease of CA IV gastric activity and serum gastrin in the 2 groups of patients studied

CONCLUSIONS

Urease test performed on biopsies sampled from patients with duodenal ulcers highlights that 17 patients in the Group no. 1 and 19 in the Group no. 2 were infected with *H. pylori*.

The measurement of CA IV activity in the parietal cells of gastric mucosa highlights an increased activity of this isoenzyme in patients with duodenal ulcer, slightly higher in Group no. 2 where *H. pylori* infection was higher.

Serum gastrin values are elevated as compared to normal values in all patients with duodenal ulcers, and they are significantly higher in Group no. 2 patients.

Following the treatment to eradicate *H. pylori* infection one reveals a decrease of CA IV gastric activity by 64% in the Group no. 1 and by 78% in the Group no. 2, whereas serum gastrin values decrease at a rate of 58% in the Group no. 1 and 69% in the Group no. 2.

The results of the study show a parallelism between the inhibition of gastric CA IV and the decrease of serum gastrin values; this parallelism correlates with the treatment efficacy since the inhibition higher percentages are present in the Group no. 2 where the patients are applied a quadruple therapy.

The study results prove the implication of CA IV isoenzyme of the gastric mucosa and gastrin in the action mechanism of the therapy conceived to eradicate *H. pylori* infection.

REFERENCES

Calam J. *Helicobacter pylori* and hormones. Yale J. Biol. Med. 1997;69:39-49.
 Chen T. S., Tsay S. H., Chang F. Y., Lee S. D. Effect of eradication of *Helicobacter pylori* on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study. Am. J. Gastroenterol. 1994;89:1511-1514.
 Frances Fischbach. Chemistry Studies. In A Manual of Laboratory and Diagnostic Tests. Lippincott Williams & Wilkins, USA, 8 Ed., 2009, 393-394.
 Harry LT Mobley, George L Mendz, and Stuart L Hazell (eds.) - *Helicobacter pylori* Physiology and Genetics, Washington (DC): ASM Press; 2001.

Graham D. Y., Opekun A., Lew G. M., Evans, Jr D. J., Klein P. D., Evans D. G. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance

of *Helicobacter (Campylobacter) pylori* infection. Am. J. Gastroenterol. 1990;85:394-398.

Grossman M.I. - Control of gastric secretion. In: Gastrointestinal Disease, edited by M.H.Sleisenger and J.S.Fordtran, Saunders, Philadelphia, 1978, pp.640-659.

Levi S., Beardshall K., Swift I., Foulkes W., Playford R., Ghosh P., Calam J. Antral *Helicobacter pylori*, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism. Br. Med. J. 1989;299:1504-1505.

Logan RP, Walker MM - [Epidemiology and diagnosis of Helicobacter pylori infection](#). BMJ 323 (7318): 920-2, 2001

Khalifah R.G. - The carbon dioxide hydration activity of carbonic anhydrase: stop-flow kinetic studies on the native human isozymes B and C. J.Biol.Chem., 1971, 246:2561-2573.

Konturek JW - [Discovery by Jaworski of Helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer](#). J. Physiol. Pharmacol. 54 Suppl 3: 23-41, 2003.

Kusters JG, van Vliet AH, Kuipers EJ - [Pathogenesis of Helicobacter pylori Infection](#). Clin Microbiol Rev 19 (3): 449-90, 2006.

Maconi G., Lazzaroni M., Sangaletti O., Bargiggia S., Vagu L., Bianchi Porro G. Effect of *Helicobacter pylori* eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am. J. Gastroenterol. 1997;92:1844-1848.

Maren T.H., Wynns G.C., Wistrand P.J. - Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme. Molec.Pharmacol., 1993, 44:901-905.

Prewett E. J., Smith J. T., Nwokolo C. U., Hudson M., Sawyerr A. M., Pounder R. E. Eradication of *Helicobacter pylori* abolishes 24-hour hypergastrinaemia: a prospective study in healthy subjects. Aliment. Pharmacol. Ther. 1991;5:283-290.

Puscas I., Coltau M., Lazoc L. - Histamine, gastrin and acetylcholine activate CA IV from parietal cells and do not modify activity of the same isozyme from the kidneys. In: Carbonic Anhydrase and Modulation of Physiologic and Pathologic Processes in the Organism, I.Puscas (ed), Helicon Publ.House, Timisoara, Romania, 1994, 524-527.



Puscas I. - Carbonic anhydrase is a modulator of vascular and secretory processes in the organism. The pH theory. *Digestion*, 1998, 59 (suppl. 3), 671.

Rotter J. L., Petersen G., Samloff I. M., McConnell R. B., Ellis A., Spence M. A., Rimoin D. L. Genetic heterogeneity of hyperpepsinogenemic I and normopepsinogenemic I duodenal ulcer disease. *Ann. Intern. Med.* 1979;91:372-377.

Stenström B, Mendis A, Marshall B - *Helicobacter pylori* - The latest in diagnosis and treatment. *Aust Fam Physician* 37 (8): 608-12, 2008.

Westblom T. U., Bhatt B. D. Diagnosis of *Helicobacter pylori* infection. *Curr. Top. Microbiol. Immunol.* 1999;241:215-235.

Wilcox M. H., Dent T. H., Hunter J. O., Gray J. J., Brown D. F., Wight D. G., Wraight E. P. Accuracy of serology for the diagnosis of *Helicobacter pylori* infection—a comparison of eight kits. *J. Clin. Pathol.* 1996;49:373-376.

Woo J. S., El-Zimaity H. M., Genta R. M., Yousfi M. M., Graham D. Y. The best gastric site for obtaining a positive rapid urease test. *Helicobacter.* 1996;1:256-259.

